PRESS RELEASE
VytronUS, Inc. Raises $49 Million Series C Financing

Sunnyvale, CA, July 29, 2016 – VytronUS, Inc. ("VytronUS"), a privately held medical device company developing novel technologies for the treatment of cardiac arrhythmias, announced today that it has secured $49 million in Series C equity financing. The current syndicate of investors enthusiastically supported this financing. Proceeds will be used for technology refinements and clinical trials of VytronUS’s proprietary Low-Intensity Collimated Ultrasound (LICU™) Cardiac Mapping & Ablation System to treat atrial fibrillation and other arrhythmias.
• READ MORE

____________________

PRESS RELEASE
VytronUS, Inc. Attracts Industry Veteran John Pavlidis
as New President and Chief Executive Officer

Sunnyvale, CA, April 6, 2015 - VytronUS, Inc. ("VytronUS"), a privately held medical device company developing novel technologies for the treatment of cardiac arrhythmias, announced today the appointment of John Pavlidis as its new president and chief executive officer and member of the Board of Directors. Pavlidis brings more than twenty-five years of medical device experience, including more than fifteen years as chief executive officer of large and small organizations.
• READ MORE

____________________

PRESS RELEASE
VytronUS, Inc. Raises $31.6 Million Series B Financing

Sunnyvale, CA, October 29, 2014 - VytronUS, Inc. ("VytronUS"), a privately held medical device company developing novel technologies for the treatment of cardiac arrhythmias, announced today that it has secured $31.6 million in an oversubscribed Series B financing. The round was led by Apple Tree Partners, along with additional new investors, BioStar Ventures, Windham Venture Partners and a strategic investor alongside New Enterprise Associates and other existing investors. Proceeds will be used for development and validation of VytronUS's proprietary Low-Intensity Collimated Ultrasound (LICU) Cardiac Imaging and Ablation System to treat atrial fibrillation and other arrhythmias in forthcoming clinical trials.
• READ MORE